Products
Blontuvetmab Biosimilar Canine Monoclonal Antibody (CD20) for Research
Pre-Made Blontuvetmab biosimilar, Canine Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Blontuvetmab is a caninized monoclonal antibody that can be potentially used in the treatment of Canine B-cell lymphoma. Specific Inquiry.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-075-1mg | 1mg | 3090 |
| GMP-Bios-ab-075-10mg | 10mg | |
| GMP-Bios-ab-075-100mg | 100mg | |
| GMP-Bios-ab-075-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Blontuvetmab biosimilar, Canine Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
| INN Name | Blontuvetmab |
| Target | CD20 |
| Format | Canine Whole mAb |
| Derivation | Caninized |
| Species Reactivity | Canine |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Unknown |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Aratana Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Canine B-cell lymphoma |
| Conditions Discontinued | na |
| Development Tech | na |
About target - MS4A1
1. Protein B-lymphocyte antigen CD20
2. Gene MS4A1
3. Organism Homo sapiens (Human)
Function
B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes (PubMed:3925015, PubMed:7684739, PubMed:12920111).
Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR (PubMed:7684739, PubMed:12920111, PubMed:18474602).
Caution
Epitope 1, mapped in PubMed:16785532, is predicted to be buried in the membrane. Its accessibility to the extracellular space, and thus to antibody recognition, is not explained.
